Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Recent Trends in Formulation and Delivery of Novel Anti-infectives
share announcement

Recent Trends in Formulation and Delivery of Novel Anti-infectives

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 6522

Special Issue Editor

Dr. Sarah Gordon

E-Mail Website
Guest Editor
Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Interests: drug delivery; liposomes; antibiotic delivery; polymer and lipid based nanocarriers

Special Issue Information

Dear Colleagues,

The continual increase in antimicrobial resistance has created an urgent need for the development of novel anti-infective compounds, acting on new targets or via innovative modes of action. Compounds designed to combat virulence by inhibiting microbial cell communication or adhesion, to interfere with efflux system function, or to disrupt membrane integrity, among other actions, may demonstrate a lower susceptibility to resistance development compared to conventional antibiotics or anti-infectives. However, such compounds often present solubility, permeability, stability, or toxicity-related challenges and require a delivery strategy for safe and effective administration.

This Special Issue aims to explore current research into formulation approaches for the delivery of novel anti-infective agents, including but not limited to quorum sensing inhibitors/antagonists, antimicrobial peptides, efflux pump inhibitors, toxin neutralizers, and anti-adhesive compounds. A broad range of formulation approaches being developed to deliver such candidates is of interest, including particulate carrier systems, hydrogels, implants, coatings, and fibers, among others. Formulation advances facilitating the co-delivery of multiple novel anti-infectives or novel anti-infectives together with conventional antibiotics/anti-infectives are also of interest.

We look forward to receiving your contributions.

Dr. Sarah Gordon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel anti-infective
  • antimicrobial peptide
  • anti-virulence
  • pathoblocker
  • quorum sensing inhibitor
  • formulation and drug delivery
  • particulate carrier systems

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 2215 KiB  
Article
Encapsulation of SAAP-148 in Octenyl Succinic Anhydride-Modified Hyaluronic Acid Nanogels for Treatment of Skin Wound Infections
by Miriam E. van Gent, Tom van Baaren, Sylvia N. Kłodzińska, Muhanad Ali, Natasja Dolezal, Bjorn R. van Doodewaerd, Erik Bos, Amy M. de Waal, Roman I. Koning, Jan Wouter Drijfhout, Hanne Mørck Nielsen and Peter H. Nibbering
Pharmaceutics 2023, 15(2), 429; https://doi.org/10.3390/pharmaceutics15020429 - 28 Jan 2023
Cited by 5 | Viewed by 1695
Abstract
Chronic wound infections colonized by bacteria are becoming more difficult to treat with current antibiotics due to the development of antimicrobial resistance (AMR) as well as biofilm and persister cell formation. Synthetic antibacterial and antibiofilm peptide (SAAP)-148 is an excellent alternative for treatment [...] Read more.
Chronic wound infections colonized by bacteria are becoming more difficult to treat with current antibiotics due to the development of antimicrobial resistance (AMR) as well as biofilm and persister cell formation. Synthetic antibacterial and antibiofilm peptide (SAAP)-148 is an excellent alternative for treatment of such infections but suffers from limitations related to its cationic peptidic nature and thus instability and possible cytotoxicity, resulting in a narrow therapeutic window. Here, we evaluated SAAP-148 encapsulation in nanogels composed of octenyl succinic anhydride (OSA)-modified hyaluronic acid (HA) to circumvent these limitations. SAAP-148 was efficiently (>98%) encapsulated with high drug loading (23%), resulting in monodispersed anionic OSA-HA nanogels with sizes ranging 204–253 nm. Nanogel lyophilization in presence of polyvinyl alcohol maintained their sizes and morphology. SAAP-148 was sustainedly released from lyophilized nanogels (37–41% in 72 h) upon reconstitution. Lyophilized SAAP-148-loaded nanogels showed similar antimicrobial activity as SAAP-148 against planktonic and biofilm-residing AMR Staphylococcus aureus and Acinetobacter baumannii. Importantly, formulated SAAP-148 showed reduced cytotoxicity against human erythrocytes, primary human skin fibroblasts and human keratinocytes. Additionally, lyophilized SAAP-148-loaded nanogels eradicated AMR S. aureus and A. baumannii colonizing a 3D human epidermal model, without inducing any cytotoxicity in contrast to SAAP-148. These findings indicate that OSA-HA nanogels increase SAAP-148′s therapeutic potential for treatment of skin wound infections. Full article
(This article belongs to the Special Issue Recent Trends in Formulation and Delivery of Novel Anti-infectives)
►▼ Show Figures

Graphical abstract

15 pages, 4458 KiB  
Article
Gallium Protoporphyrin Liquid Crystalline Lipid Nanoparticles: A Third-Generation Photosensitizer against Pseudomonas aeruginosa Biofilms
by Muhammed Awad, Timothy J. Barnes, Nicky Thomas, Paul Joyce and Clive A. Prestidge
Pharmaceutics 2022, 14(10), 2124; https://doi.org/10.3390/pharmaceutics14102124 - 06 Oct 2022
Cited by 7 | Viewed by 2600
Abstract
The looming antimicrobial resistance pandemic has encouraged the investigation of antimicrobial photodynamic therapy (aPDT) as a promising technology to combat recalcitrant bacterial infections caused by antibiotic resistant strains. Here, we report on the optimization and effective application of gallium protoporphyrin liquid crystalline lipid [...] Read more.
The looming antimicrobial resistance pandemic has encouraged the investigation of antimicrobial photodynamic therapy (aPDT) as a promising technology to combat recalcitrant bacterial infections caused by antibiotic resistant strains. Here, we report on the optimization and effective application of gallium protoporphyrin liquid crystalline lipid nanoparticles (GaPP-LCNP) as a photosensitizer for aPDT against the Gram-negative bacteria P. aeruginosa in both planktonic and biofilm modes of growth. LCNP significantly enhanced the performance of GaPP as photosensitizer by two-fold, which was correlated with higher antibacterial activity, reducing the viability of planktonic P. aeruginosa by 7 log10 using 0.8 µM GaPP-LCNP and a light dose of 17 J.cm−2. Importantly, GaPP-LCNP also reduced the viability of biofilms by 6 log10 at relatively low light dose of 34.2 J.cm−2 using only 3 µM GaPP-LCNP. The high antibiofilm activity of GaPP-LCNP at low GaPP-LCNP dose indicated the high efficiency and safety profile of GaPP-LCNP as a promising platform for photodynamic inactivation of recalcitrant infections. Full article
(This article belongs to the Special Issue Recent Trends in Formulation and Delivery of Novel Anti-infectives)
►▼ Show Figures

Graphical abstract

18 pages, 4166 KiB  
Article
Characterization and Differential Cytotoxicity of Gramicidin Nanoparticles Combined with Cationic Polymer or Lipid Bilayer
by Yunys Pérez-Betancourt, Rachel Zaia, Marina Franchi Evangelista, Rodrigo Tadeu Ribeiro, Bruno Murillo Roncoleta, Beatriz Ideriha Mathiazzi and Ana Maria Carmona-Ribeiro
Pharmaceutics 2022, 14(10), 2053; https://doi.org/10.3390/pharmaceutics14102053 - 27 Sep 2022
Cited by 2 | Viewed by 1627
Abstract
Gramicidin (Gr) nanoparticles (NPs) and poly (diallyl dimethyl ammonium) chloride (PDDA) water dispersions were characterized and evaluated against Gram-positive and Gram-negative bacteria and fungus. Dynamic light scattering for sizing, zeta potential analysis, polydispersity, and colloidal stability over time characterized Gr NPs/PDDA dispersions, and [...] Read more.
Gramicidin (Gr) nanoparticles (NPs) and poly (diallyl dimethyl ammonium) chloride (PDDA) water dispersions were characterized and evaluated against Gram-positive and Gram-negative bacteria and fungus. Dynamic light scattering for sizing, zeta potential analysis, polydispersity, and colloidal stability over time characterized Gr NPs/PDDA dispersions, and plating and colony-forming units counting determined their microbicidal activity. Cell viabilities of Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans in the presence of the combinations were reduced by 6, 7, and 7 logs, respectively, at 10 μM Gr/10 μg·mL−1 PDDA, 0.5 μM Gr/0. 5μg·mL−1 PDDA, and 0.5 μM Gr/0.5 μg·mL−1 PDDA, respectively. In comparison to individual Gr doses, the combinations reduced doses by half (S. aureus) and a quarter (C. albicans); in comparison to individual PDDA doses, the combinations reduced doses by 6 times (P. aeruginosa) and 10 times (C. albicans). Gr in supported or free cationic lipid bilayers reduced Gr activity against S. aureus due to reduced Gr access to the pathogen. Facile Gr NPs/PDDA disassembly favored access of each agent to the pathogen: PDDA suctioned the pathogen cell wall facilitating Gr insertion in the pathogen cell membrane. Gr NPs/PDDA differential cytotoxicity suggested the possibility of novel systemic uses for the combination. Full article
(This article belongs to the Special Issue Recent Trends in Formulation and Delivery of Novel Anti-infectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop